Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERACYTE, INC.VCYT · Entity 2018 | EVP, Gen Counsel and Secretary | March 03, 2017 | March 06, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERACYTE, INC.
Report date March 03, 2017 · Filed March 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,162 |
Reported balance
After 2017-01-31 transaction · row 1
1 source rowRow 1 · 2017-01-31 · Grant · Acquired 377 · Balance 4,162 F1: Purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.05 · Expires 2027-03-03 | Direct | 60,000 |
Reported balance
After 2017-03-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-03 · Grant · Acquired 60,000 · Balance 60,000 F2: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan.
F2: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2017 Filed Mar 6, 2017 17:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-17-000020 · wf-form4_148883822860329.xml · derivative · entry 2 Brooks Julie · CIK 0001474896 · EVP, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-03-03 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| January 31, 2017 Filed Mar 6, 2017 17:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 377 | $4.23 | $1,594.71 |
DisclosureSEC source: 0001384101-17-000020 · wf-form4_148883822860329.xml · nonDerivative · entry 1 Brooks Julie · CIK 0001474896 · EVP, Gen Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,162 F1 · shares: Purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.